Becton, Dickinson and Company (BDX)

NYSE · Franklin Lakes, New Jersey, USA · Founded 1897 · CEO Tom Polen

Valuation summary

$120.83 fair value versus $212.68 in the market, a difference of -43.2%. Rated Sell.

Fair value per share$120.83
Current share price$212.68
Upside / downside-43.2%
Bear case$61.12
Bull case$208.61
Discount rate (WACC)8.4%
Terminal growth2.50%
Market capitalisation$58B
EV / Sales3.7x

About Becton, Dickinson and Company

Founded in 1897 by Maxwell Becton and Fairleigh Dickinson. Tom Polen has been chief executive since 2020. BD is one of the largest medical technology companies, making syringes, needles, IV catheters and infusion pumps used in nearly every hospital, plus surgical and interventional devices. In February 2026 it combined its biosciences and diagnostics business with Waters Corporation, leaving a more focused medical technology company.

Investment case

  • Products used in almost every hospital procedure give steady, recurring demand.
  • Prefilled syringe demand from biologic and GLP-1 drugs is growing.
  • The Waters deal simplifies the company and funded debt reduction.

Key risks

  • Infusion pump recalls and quality problems have hurt it before.
  • Tariffs and China volume-based purchasing pressure prices.
  • Growth is only mid-single digits.

Revenue by segment

Medical Essentials30%
Connected Care25%
BioPharma Systems15%
Interventional30%

Five-year forecast

RevenueFree cash flow
Year 1$18.6B$3.3B
Year 2$17.7B$3.1B
Year 3$17.2B$3.0B
Year 4$17.1B$3.0B
Year 5$17.5B$3.0B

What the street says

A defensive medtech in transition; investors want to see faster growth after the separation.

Comparable companies: BIIB · TEVA · TAK · GSK · ZTS · PFE · BSX · MDT

Open the interactive model, price chart and sensitivity grid →